| 4.86 -0.03 (-0.61%) | 10-24 14:53 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 8.26  |
1-year : | 10.28 |
| Resists | First : | 7.07 |
Second : | 8.8 |
| Pivot price | 5.29  |
|||
| Supports | First : | 4.26 |
Second : | 3.55 |
| MAs | MA(5) : | 4.75 |
MA(20) : | 5.56 |
| MA(100) : | 3.6 |
MA(250) : | 7.26 |
|
| MACD | MACD : | -0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 9.6 |
D(3) : | 8.9 |
| RSI | RSI(14): 48.5 |
|||
| 52-week | High : | 24.14 | Low : | 2.14 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ KLRS ] has closed above bottom band by 40.2%. Bollinger Bands are 163.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 19 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 5 - 5.03 | 5.03 - 5.05 |
| Low: | 4.33 - 4.37 | 4.37 - 4.4 |
| Close: | 4.84 - 4.89 | 4.89 - 4.94 |
Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.
Mon, 15 Sep 2025
80-Patient Phase 1b/2 Trial: Kalaris Tests Revolutionary AMD Drug from Lasker Award Winner - Stock Titan
Thu, 04 Sep 2025
Kalaris Eyes A Game-Changing Breakthrough In Anti-VEGF Therapy With TH103 To Treat
retinal Disease - RTTNews
Wed, 03 Sep 2025
Kalaris Therapeutics Peeks Ahead: Strong Cash Reserves Empower Vital Trials - StocksToTrade
Mon, 01 Sep 2025
Kalaris Therapeutics Inc. (KLRS) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 19 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 14.2 (%) |
| Held by Institutions | 69.9 (%) |
| Shares Short | 681 (K) |
| Shares Short P.Month | 187 (K) |
| EPS | -2.72 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.83 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -32 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -1.79 |
| PEG Ratio | 0 |
| Price to Book value | 1.7 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.83 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|